NICE guidance and advice

Advice

NICE has published several technology appraisals relating to licensed indications for the intravenous formulation of rituximab. The use of rituximab for scleroderma is not appropriate for referral for a NICE technology appraisal and is not currently planned into any other work programme.

NICE has not issued any clinical guidelines on managing scleroderma but has published the following advice relating to this condition:

scleroderma: oral mycophenolate
digital ulcers: sildenafil